1 Reason Every Investor Should Know About AbbVie (ABBV)

Key Points

• AbbVie more than tripled its dividend payout over the past decade.

• AbbVie's former lead drug, Humira, lost patent protection more than 20 years after it launched.

• Humira losses are being offset by recently launched drugs.

• 10 stocks we like better than AbbVie ›

With patent-protected market exclusivity for their products, pharmaceutical companies reliably produce profits that they aren't shy about distributing to shareholders. In an industry already known for relatively strong dividend payout raises, AbbVie (NYSE: ABBV) stands out with a quarterly payment that has soared 221.6% over the past decade.

Image source: Getty Images.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »

An ability to retain exclusivity for its former lead drug is how AbbVie delivered a 494% total return over the past decade. The company spun off from Abbott Laboratories in 2013 to limit the parent's exposure to a looming patent cliff for Humira, an injectable anti-inflammation treatment for people with arthritis, psoriasis, and other autoimmune disorders that launched in 2003.

Composition of matter patents are generally good for 25 years, which gives drugmakers a little over a decade of exclusivity following the typical new drug development process. AbbVie employed a thicket of additional patents that held off biosimilar competition for Humira in the U.S. market until 2023.

AbbVie's new lead drug, Skyrizi, is also an injectable treatment. Injectable drugs involve complicated manufacturing and administration processes, which means there are extra opportunities to extend their exclusivity periods.

Sales of Skyrizi bounded 69% higher year over year in the first half of 2025 to $7.8 billion. That's outstanding for a drug that launched in 2019, and it's not the only treatment offsetting Humira losses for AbbVie. Rinvoq, an arthritis drug that also launched in 2019, racked up $3.7 billion in sales during the first half of 2025. Despite Humira sales that shrank by more than half, total first-half revenue is up by 8% this year.

At recent prices, AbbVie offers a juicy 3.1% dividend yield. If AbbVie can extend exclusivity periods for Rinvoq and Skyrizi as effectively as it did for Humira, shareholders could see their payments surge in the decade ahead, too.

Should you invest $1,000 in AbbVie right now?

Before you buy stock in AbbVie, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AbbVie wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $670,781!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,023,752!*

Now, it’s worth noting Stock Advisor’s total average return is 1,052% — a market-crushing outperformance compared to 185% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.

See the 10 stocks »

*Stock Advisor returns as of August 25, 2025

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbbVie and Abbott Laboratories. The Motley Fool has a disclosure policy.